# Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy

> **NCT00420303** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Spondylarthropathies, Enthesitis

## Interventions

- **DRUG:** Etanercept
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00420303
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2010-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420303, "Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00420303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*